Forecast to Publish a Funding Opportunity Announcement for Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for organizations developing advanced informatics technologies for cancer research. Eligible applicants include research institutions, universities, and nonprofits with expertise in cancer informatics. Projects must involve emerging technologies that have moved beyond initial prototyping. The technology should address needs across the cancer research continuum: biology, treatment, diagnosis, detection, prevention, epidemiology, or health disparities.
Applications must demonstrate how the technology will benefit the cancer research field and involve mechanisms to gather user feedback during development. Strong proposals include plans for user engagement, training, outreach, and collaboration with the target research community. A realistic development timeline with clear milestones is required.
This funding opportunity has not yet opened. The forecast announcement allows potential applicants time to develop collaborations and prepare competitive applications.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Jul 2, 2025 Applications open
- Nov 21, 2025 Application deadline
- Jul 1, 2026 Award announced
- Jul 1, 2026 Project start
Program description
The National Cancer Institute intends to publish a Notice of Funding Opportunity (NOFO) to invite applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and cancer health disparities. As a component of the NCI’s Informatics Technology for Cancer Research (ITCR) Program, this NOFO will focus on advancing emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. To be successful, proposed development plans must have a clear rationale for why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from driving cancer research projects as well as the broader user community throughout the development process must be included.
This NOFO will invite applications for the enhancement and dissemination of emerging, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research. The emphasis will be on uniqueness and potential impact on cancer research. In addition, all projects proposed in response to this NOFO must involve the following general attributes:
- Potential to advance driving cancer research projects and the cancer research field in general;
- Offers clear advantages over competing technologies in the targeted cancer research domain;
- Provides compelling plans and processes for supporting and engaging end users to evaluate and apply the tool or resource;
- Provides plans for advancing use of the tool or resource by the targeted community through collaboration, outreach, and training;
- Provides a realistic timeline and milestones for technology development.
Applications are not being solicited at this time. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This NOFO will utilize the U24 activity code. Investigators with expertise and insights into cancer informatics are encouraged to begin to consider applying for this NOFO.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- SF-424 (R&R) form
- Project Narrative/Research Plan
- Budget and Budget Justification
- Biographical Sketches (key personnel)
- Letters of Support (from user community/driving research projects)
- Data Management Plan
- Facilities and Resources
Program contact
- 👤 Juli Klemm, PhD National Cancer Institute
- 📧 juli.klemm@nih.gov
- 📞 202-853-7889
Funding track record
Recent awards under CFDA 93.399 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$22,629,848
-
$20,187,190
-
$19,625,661
-
$19,227,026
-
$18,138,327
-
$17,827,646
-
$17,614,587
-
$16,535,118
-
$16,126,587
-
$14,347,054
Top States by Funding
- NY 7 awards $57.6M
- SC 3 awards $46.6M
- DE 3 awards $43.2M
- IL 3 awards $38.4M
- WI 3 awards $37.9M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.395). How funding has trended year over year.
| 2024 | $1,298,551,504 | |
| 2025 | $1,414,965,434 | |
| 2026 est. | $926,626,977 |
FAQ
What types of organizations can apply for this grant?
Research institutions, universities, and nonprofits with capacity to develop informatics technologies for cancer research. Your organization must have expertise in cancer informatics or partner with experts who do.
What stage of development must my technology be at?
Your technology must have completed initial prototyping and pilot testing. It should show potential for significant impact but not yet be widely adopted in cancer research.
When will this grant opportunity open?
The exact opening date has not been announced. A Notice of Funding Opportunity will be published, likely with a November 2025 deadline. Watch the NIH grants website for the official announcement.
What makes an application competitive?
Strong applications clearly justify why the technology is needed, offer advantages over competing solutions, and include detailed plans for engaging end users. Demonstrate collaboration, training, and outreach strategies.
Must I cost-share or provide matching funds?
No cost-sharing is required for this cooperative agreement award.
💡 Tips for applicants
- Start building your user community now. Identify the cancer research projects and researchers who will benefit from your technology. Their input will strengthen your application.
- Emphasize the unique advantages of your technology. Clearly explain why it's better than existing solutions for your specific cancer research domain.
- Develop a detailed engagement plan. Show how you'll gather feedback from users, provide training, and support adoption throughout the development process.
- Create a realistic timeline with measurable milestones. Reviewers want to see specific, achievable development goals with clear decision points.
- Build partnerships early. Involve collaborators from target cancer research communities before submitting. Letters of support from driving research projects add credibility.
⚠️ Common mistakes
Applications lack clear justification for why the technology is needed or how it advances the field beyond existing tools. Weak user engagement and dissemination plans—reviewers expect detailed strategies for training, outreach, and community adoption. Unrealistic timelines, vague milestones, or insufficient detail on how development will proceed.
Similar grants
- CLOSED Forecast to Publish a Funding Opportunity Announcement for Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) — National Institutes of Health
- CLOSED Forecast to Publish a Funding Opportunity Announcement for Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) — National Institutes of Health
- OPEN Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) — National Institutes of Health